TL;DR
A bioRxiv preprint reports protein changes in ovarian tissue from women aged 50 to 75, suggesting the organ continues to change decades after menopause. The study examined 28 ovaries and is not peer-reviewed; its findings do not establish effects on health or cancer risk.
A preliminary study of 28 postmenopausal ovaries found age-associated changes in proteins linked to inflammation, tissue remodeling and cell signaling, challenging the idea that ovaries become biologically inactive after menopause. The report, posted on bioRxiv, has not been peer-reviewed, and it does not show that the observed changes cause illness or alter ovarian cancer risk.
The researchers analyzed histologically normal ovarian tissue from women aged 50 to 75, dividing the samples into three groups: ages 50–59, 60–69 and 70 or older. Using mass spectrometry, they quantified 5,812 protein groups and compared their levels across age groups. The study also assessed overlap with proteins previously associated with ovarian cellular senescence and ovarian cancer.
Compared with the 50–59 group, the 60–69 group had significant changes in 40 protein groups: 34 were higher and six lower. In the 70-and-older group, 117 protein groups differed significantly from the youngest group. Of those, 84 were lower and 33 higher. The report linked increases to immune responses, inflammation, tissue remodeling and cellular responses to damage; many declining proteins were associated with maintaining ovarian cell and tissue structure.
The team also identified a 26-protein signature of postmenopausal ovarian aging, which it named the Buck Postmenopausal Ovary Molecular Signature, or BuckPOMS. Seventeen proteins showed significant changes in both comparisons with the youngest age group. The authors describe a shift in the overall pattern from structural and epithelial-associated proteins toward signals involving extracellular remodeling and communication between cells.
Why Postmenopausal Tissue Changes Matter
The findings add evidence that ovarian tissue continues to change with age after reproductive function has ended. Researchers have often treated the postmenopausal ovary as largely inactive, but this study’s protein measurements point to ongoing molecular processes. Understanding those processes could help frame future research into how ovarian aging relates to health later in life.
The work may also inform research questions about ovarian cancer and tissue aging, because some analyzed proteins have previously been associated with cancer or cellular senescence. But the study did not test whether the protein patterns predict cancer, cause disease, or affect an individual’s health. Its small sample and preliminary status mean the results are a starting point for further investigation, not a basis for clinical decisions.
As an affiliate, we earn on qualifying purchases.
How Researchers Examined Older Ovaries
Ovaries contain a finite supply of eggs that declines with age, and menopause marks the end of reproductive years. Women may live for decades after menopause, making changes in that period a subject of growing research interest. The ovaries have also been described as producing hormones such as androgens and molecules involved in cell communication after menopause, although this study focused on tissue proteins rather than measuring health effects across the body.
Earlier research has reported age-related changes in ovarian gene activity, including processes linked to metabolism, cellular stress and communication between cells. The report says much of that work involved small groups or focused on women before or around menopause. The new analysis addresses part of that research gap by comparing tissue samples across three postmenopausal age ranges, but its 28-sample size limits how broadly its results can be applied.
“The human ovary exhibits dynamic molecular remodeling in the decades post-menopause.”
— The study authors, as described in the report
As an affiliate, we earn on qualifying purchases.
Limits of the Protein Findings
The work is a non-peer-reviewed preprint, and its sample includes only 28 women aged 50 to 75. The report describes differences between age groups, but the study design does not establish that age alone caused them or show how the measured protein patterns affect health in living patients.
It is also unclear whether the identified 26-protein signature will be reproduced in larger or more diverse groups, or whether it can distinguish normal aging from disease. The reported overlap with proteins associated with ovarian cancer does not demonstrate a link to cancer risk. The study did not establish that the findings can be used for screening, prevention or treatment.
postmenopausal hormone balance supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Replication and Further Study Needed
The immediate next step is peer review and independent replication in larger studies. Researchers would also need to test whether the protein patterns appear consistently across populations and whether they correspond to measurable changes in ovarian function or health outcomes.
Further work could examine whether the BuckPOMS signature has practical research value and how it relates to ovarian cancer or other conditions. Until those questions are answered, the results should be understood as an early map of molecular changes in postmenopausal tissue—not as evidence of a new diagnosis or a reason to change medical care.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the study find?
Researchers reported age-associated changes in protein levels in ovarian tissue from women aged 50 to 75, including patterns linked to inflammation and tissue remodeling.
Does the research show that ovaries remain fully functional after menopause?
No. The study measured proteins in tissue samples. It suggests that molecular activity and remodeling continue, but it does not show that ovaries retain reproductive function or establish the effects of the changes on the body.
Does this study show that ovarian cancer risk increases?
No. The authors compared some findings with proteins previously associated with ovarian cancer, but the study did not test cancer risk or show that the protein changes cause cancer.
Can people use the findings to guide health decisions?
No. The report is a preliminary, non-peer-reviewed preprint and is not a clinical study establishing a screening or treatment approach. Health decisions should be discussed with a qualified health professional.
Source: rss
